Yizhou Dong, PhD
About Me
Dr. Yizhou Dong is the Mount Sinai Endowed Professor in Nanomedicine with the Icahn Genomics Institute, the Marc and Jennifer Lipzhultz Precision Immunology Institute (PrIISM), the Department of of Immunology and Immunotherapy, and the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai.
Dr. Dong’s research focuses on the design and development of delivery systems and RNA therapeutics for the treatment of cancer, genetic disorders, and infectious diseases. His lab will integrate their specialty in pharmaceutics, pharmaceutical chemistry, biomedical engineering, materials formulation, and animal studies to design novel therapeutic medicines and uncover their mechanisms of actions. Recognized as a leader in the fields of lipid nanoparticle (LNP) and RNA therapeutics, Dr. Dong has authored over 100 papers and has over 100 patents. Many of his inventions have been licensed and are currently under development as drug candidates for clinical trials.
Dr. Dong is the recipient of Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences (NIGMS), Ohio State Early Career Innovator of the Year, and The American Association of Pharmaceutical Scientists (AAPS) Emerging Leader Award. He is an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE) and also an elected fellow of the National Academy of Inventors. Dr. Dong received his B.S. in Pharmaceutical Sciences from Peking University, Health Science Center and his M.S. in Organic Chemistry from Shanghai Institute of Organic Chemistry. In 2009, he received his Ph.D. degree in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill (UNC-CH) and then did a postdoctoral fellowship in the lab of Robert Langer and Daniel Anderson at MIT. He was appointed as an Assistant Professor at OSU in 2014 and promoted to Associate Professor in 2018. He joined Mount Sinai as a tenured professor in 2022.
Visit the Dong Lab Website Here.
Language
English
Position
PROFESSOR | Immunology & Immunotherapy, PROFESSOR | Oncological Sciences
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Dong during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Arbor Biotechnologies
- FLAGSHIP LABS 85
- Merck Sharp & Dohme Corp
- CSL Behring
- Moonwalk Biosciences, Inc
- SIRNAGEN THERAPEUTICS, INC.
- Pfizer Inc., U.S. Pharmaceuticals Group
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Immunanoengineering Therapeutics, LLC
Founder/Co-Founder/Partner
- Immunanoengineering Therapeutics, LLC
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.